Blood Transfusion Market Size, Share, Competitive Landscape and Trend Analysis Report, by Type, by Application : Global Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics

The blood transfusion market is driven by the growing prevalence of anemia, a condition characterized by a lower-than-normal number of red blood cells or hemoglobin concentration. Anemia primarily affects women and children, with severe cases leading to poor cognitive and motor development in children and complications for pregnant women and their babies. The condition arises from insufficient hemoglobin to transport oxygen to the body's organs and tissues, often due to poor nutrition, infections, chronic diseases, heavy menstruation, pregnancy complications, or hereditary factors. Iron deficiency is a common cause of anemia, which predominantly impacts children under five, especially those under two years, menstruating adolescent girls and women, and pregnant and postpartum women.

Globally, anemia affects approximately half a billion women aged 15–49 and 269 million children aged 6–59 months. In 2019, anemia affected 30% (539 million) of non-pregnant women and 37% (32 million) of pregnant women in the same age group, according to the WHO Global Anemia Estimates, 2021 Edition. These statistics underscore the critical demand for blood transfusions to manage and treat anemia, significantly influencing the blood transfusion market.

The blood transfusion market faces restraints due to the risk of allergic reactions among recipients, even when they receive the correct blood type. These reactions can manifest as hives and itching, and while they can typically be managed with antihistamines, there is still a need for medical consultation if the reaction becomes severe. The potential for such adverse reactions highlights a significant concern in blood transfusion procedures, potentially limiting their use and acceptance among patients and healthcare providers. This necessity for additional medical intervention and the associated risks may hinder the market growth by reducing patient confidence and increasing the need for alternative treatments.

The blood transfusion market is poised for significant growth opportunities driven by the integration of advanced omics technologies. Blood transfusion is the most common in-hospital medical procedure, crucial for saving millions of lives annually. The logistical strategy of blood bank storage, which ensures the availability of approximately 110 million units each year, is essential for meeting this demand. However, traditional storage methods induce biochemical and morphological changes in red blood cells, potentially compromising their integrity and functionality, which can adversely affect transfusion outcomes. Omics technologies offer a transformative potential by enabling personalized transfusion medicine.

This emerging discipline aims to tailor additives, processing, and storage strategies to individual recipients, optimizing the efficacy and safety of transfusions. As these personalized approaches become more refined, this technology is set to revolutionize the field of blood transfusion, improving patient outcomes and enhancing the overall effectiveness of transfusion practices.

Global Blood Transfusion Market

The WHO report published on June 2, 2023, underscores the critical disparities in blood transfusion access across different income groups. Approximately 118.54 million blood donations are collected worldwide, with 40% originating from high-income countries, which house only 16% of the global population. There are significant variations in blood collection practices among 13, 300 blood centers across 169 countries. High-income countries report a median annual collection of 25, 700 donations per center, compared to 9, 300 in upper-middle-income, 4, 400 in lower-middle-income, and 1, 300 in low-income countries.

The whole blood donation rate further highlights this inequality, with high-income countries achieving a median of 31.5 donations per 1, 000 people, while upper-middle, lower-middle, and low-income countries report 16.4, 6.6, and 5.0 donations per 1, 000 people, respectively. Notably, in low-income countries, up to 54% of blood transfusions are administered to children under five, whereas in high-income countries, 76% of transfusions are for patients over 60 years of age. This data reveals the urgent need for improved blood collection and distribution strategies in lower-income regions to ensure timely and equitable access to safe blood.

Median Annual Donations per Blood Center

Market Segmentation

The blood transfusion market is segmented into type, application, and region. On the basis of type the market is divided into Y-type, straight, and others. As per application, the market is segregated into child and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional Market Outlook

The blood transfusion market in North America is characterized by its vital role in supporting various medical procedures and treatments. Every two seconds, someone in the United States needs blood, underlining its importance in operations, cancer treatments, chronic illness management, and catastrophic injury care. With approximately 7 million blood donors and over 14 million units of blood transfused annually in the U.S., the demand for blood products is substantial. The healthcare system in the U.S. relies heavily on around 29, 000 units of red blood cells daily to cater to patient needs, emphasizing the critical need for a robust blood supply network and ongoing blood donations. Advanced transfusion medicine techniques, including personalized approaches and enhanced safety protocols, are anticipated to further optimize transfusion outcomes, driving growth within the North American blood transfusion market.

• On November 16, 2023, Grifols, a prominent manufacturer of plasma-derived medications and cutting-edge diagnostic solutions, unveiled its latest innovation: the Grifols sCD38 solution. This groundbreaking product, the first of its kind in the industry, was developed to counteract anti-CD38 antibodies in multiple myeloma patients undergoing daratumumab therapy. Its primary function was to facilitate swift and precise blood transfusion tests, which are crucial for effective treatment.
• In September 2023, GSK plc announced that the US Food and Drug Administration (FDA) had approved Ojjaara (momelotinib) for treating intermediate or high-risk myelofibrosis in adults with anaemia. This included both primary myelofibrosis and secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia) . Ojjaara, an oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor taken once daily, became the sole approved medication for addressing key disease manifestations such as anaemia, constitutional symptoms, and splenomegaly (enlarged spleen) in both newly diagnosed and previously treated myelofibrosis patients with anaemia.

Competitive Landscape

The major players operating in the blood transfusion market include F. Hoffmann-La Roche AG, Abbott, BIO KIT (Werfen) , Ortho Clinical Diagnostics, Bio-Rad Laboratories, Immucor Inc., BAG Healthcare GmbH, Danaher, Quotient Limited, and DiaSorin S.P.A.

Recent Key Strategies and Developments

• In January, 2024, HORIBA Medical introduced the HELO 2.0, a cutting-edge automated hematology platform that received CE-IVDR approval and awaited approval from the US FDA. Building on the achievements of its predecessor, the new HELO was developed in collaboration with customers to enhance performance and address the full spectrum of requirements for high-throughput automated hematology.
• In May 2023, the NHS introduced a novel genetic blood-matching test for thousands of individuals living with sickle-cell disease or thalassemia, aiming to diminish the painful side-effects associated with transfusion treatments.
• On September 14, 2021, a new national initiative was launched by the American Red Cross aimed at increasing the participation of Black blood donors to support patients with sickle cell disease and enhance health outcomes.

Industry Trends

• In November 2022, a groundbreaking clinical trial marked the first time that laboratory-grown red blood cells were transfused into another person. These manufactured blood cells were derived from stem cells obtained from donors. In the RESTORE randomized controlled clinical trial, the lab-grown red cells were successfully transfused into volunteers. This historic event represented the first instance of red blood cells, cultivated in a laboratory setting, being administered to another individual as part of a blood transfusion trial.
• On April 13, 2021, the biotechnology company EryPharm announced the launch of a medical device designed to mass-produce cultured red blood cells, aiming to develop new sources for blood transfusions.

Key Sources Referred

1. The American National Red Cross
2. WHO
3. Association for the Advancement of Blood & Biotherapies
4. Abbott
5. Blood Centers of America
6. Bristol Myers Squibb
7. Institute For Health Metrics and Evaluation

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blood transfusion market analysis from 2024 to 2033 to identify the prevailing blood transfusion market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the blood transfusion market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global blood transfusion market trends, key players, market segments, application areas, and market growth strategies.